These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients]. Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938 [TBL] [Abstract][Full Text] [Related]
5. Clinical significance of correction of serum beta 2-microglobulin levels for serum creatinine in multiple myeloma. Scudla V; Vavrdová V; Budíková M; Indrák K Acta Univ Palacki Olomuc Fac Med; 1991; 131():257-64. PubMed ID: 1840347 [TBL] [Abstract][Full Text] [Related]
6. [Serum ferritin and beta-2-microglobulin in multiple myeloma]. Linkesch W; Ludwig H Acta Med Austriaca; 1982; 9(5-6):227-31. PubMed ID: 6187172 [TBL] [Abstract][Full Text] [Related]
7. Serum ferritin and beta 2-microglobulin in patients with multiple myeloma. Linkesch W; Ludwig H Cancer Detect Prev; 1983; 6(1-2):297-301. PubMed ID: 6192921 [TBL] [Abstract][Full Text] [Related]
8. Stratification of multiple myeloma according to serum beta 2-microglobulin and serum albumin levels. Scudla V; Budíková M; Fischerová E; Zadrazil J; Indrák K Acta Univ Palacki Olomuc Fac Med; 1991; 130():201-12. PubMed ID: 1838869 [TBL] [Abstract][Full Text] [Related]
9. [Prognostic value of serum beta2-microglobulin in multiple myeloma]. Bettini R; Redaelli S; Maino C; Bertuol S; Costantini C; Lazzarini A; Brivio L; Gorini M Recenti Prog Med; 2005 Feb; 96(2):81-6. PubMed ID: 15844767 [TBL] [Abstract][Full Text] [Related]
10. [The prognosis of patients with multiple myeloma--the aspect of histological distribution to the renal tissue and serum level of beta 2-MG]. Inoue Y; Suzuki K; Enomoto H; Takemura T; Nakamura K Rinsho Ketsueki; 1992 Aug; 33(8):1012-6. PubMed ID: 1404855 [TBL] [Abstract][Full Text] [Related]
11. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression. Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271 [TBL] [Abstract][Full Text] [Related]
12. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933 [TBL] [Abstract][Full Text] [Related]
13. [The significance of lactate dehydrogenase and beta 2-microglobulin levels for the assessment of the prognosis and choice of therapy in multiple myeloma]. Iakovleva SV; Andreeva NE; Izgorodin AS Ter Arkh; 1995; 67(7):35-9. PubMed ID: 7482303 [TBL] [Abstract][Full Text] [Related]
14. Type III procollagen N-peptide correlates with beta-2-microglobulin in myelomatosis. Hasselbalch HC; Bjerrum OW; Junker P Clin Lab Haematol; 1995 Sep; 17(3):237-41. PubMed ID: 8719897 [TBL] [Abstract][Full Text] [Related]
15. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762 [TBL] [Abstract][Full Text] [Related]
16. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment. Urbańska-Ryś H; Robak T Mediators Inflamm; 2003 Aug; 12(4):229-35. PubMed ID: 14514474 [TBL] [Abstract][Full Text] [Related]
18. [Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis]. Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V Vnitr Lek; 1991 Apr; 37(4):342-51. PubMed ID: 2053304 [TBL] [Abstract][Full Text] [Related]
19. [Prognostic value of some biochemical and immunologic factors in the management of multiple myeloma]. Abdulkadyrov KM; Stel'mashenko LV; Bessmel'tsev SS; Lubo-Lesnichenko IF; Sel'tser AV; Rozanova OE; Gubarenko NK; Bubnova LN; Mnuskina MM; Zhuchikhina AA; Blinov MN; Gritskevich NL Vopr Onkol; 1998; 44(3):304-9. PubMed ID: 9695777 [TBL] [Abstract][Full Text] [Related]
20. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count. Perosa F; Minoia C; Favoino E; Prete M; Dammacco F Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]